/
Oncology
Head and Neck Squamous Cell Carcinoma (HNSCC)
14
Pipeline Programs↗
11
Active Trials↗
10
Companies Involved↗
Head and Neck Squamous Cell Carcinoma (HNSCC) is an emerging landscape with 14 programs across 10 companies. The most active players are Regeneron, Sutro Biopharma, Inc..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical7
Phase 25
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
63%
Monoclonal antibody
5 of 8 classified programs — the dominant modality here.
Monoclonal antibody leads; the ring shows all 8 classified programs, each share of the total. Modality classified for 64% of 14 pipeline programs.
Analysis
Trial Status
12
clinical trials
Recruiting5 · 42%
Not yet recruiting4 · 33%
Active, not recruiting2 · 17%
Completed1 · 8%
Clinical Trials
Trial Activity
12 trials
A Phase II Neoadjuvant Study of the Safety and Tolerability of Anti-PD1 (Nivolumab) Administered Alone or in Combination With Anti-LAG3 (Relatlimab) or Anti-CTLA4 (Ipilimumab) in Resectable Head and Neck Cancer
Active, not recruiting·—·Phase 2·NCT04080804·80 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)